Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Other Accumulated Expenses (2022 - 2025)

CervoMed's Other Accumulated Expenses history spans 8 years, with the latest figure at $2.1 million for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses rose 47.81% year-over-year to $2.1 million; the TTM value through Mar 2025 reached $2.1 million, up 47.81%, while the annual FY2024 figure was $2.4 million, 22.48% up from the prior year.
  • Other Accumulated Expenses for Q1 2025 was $2.1 million at CervoMed, down from $2.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.4 million in Q4 2024 and bottomed at $532550.0 in Q2 2023.
  • The 4-year median for Other Accumulated Expenses is $1.5 million (2022), against an average of $1.5 million.
  • The largest YoY upside for Other Accumulated Expenses was 200.08% in 2023 against a maximum downside of 68.09% in 2023.
  • A 4-year view of Other Accumulated Expenses shows it stood at $644252.0 in 2022, then soared by 200.08% to $1.9 million in 2023, then grew by 22.48% to $2.4 million in 2024, then dropped by 12.05% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Other Accumulated Expenses are $2.1 million (Q1 2025), $2.4 million (Q4 2024), and $2.2 million (Q3 2024).